(Q34512144)

English

Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 August 2017

0 references

Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials (English)

1 reference

Europe PubMed Central

2 August 2017

1 reference

based on heuristic

inferred from title

9

object named as

Alex A Adjei

1 reference

Europe PubMed Central

2 August 2017

Julian R Molina

7

object named as

Julian R Molina

1 reference

Europe PubMed Central

2 August 2017

6

object named as

James R Jett

1 reference

Europe PubMed Central

2 August 2017

author name string

Nathan R Foster

1

1 reference

Europe PubMed Central

2 August 2017

Yingwei Qi

2

1 reference

Europe PubMed Central

2 August 2017

Qian Shi

3

1 reference

Europe PubMed Central

2 August 2017

James E Krook

4

1 reference

Europe PubMed Central

2 August 2017

John W Kugler

5

1 reference

Europe PubMed Central

2 August 2017

Steven E Schild

8

1 reference

Europe PubMed Central

2 August 2017

Sumithra J Mandrekar

10

1 reference

Europe PubMed Central

2 August 2017

language of work or name

0 references

publication date

19 October 2010

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

2 August 2017

117

1 reference

Europe PubMed Central

2 August 2017

6

1 reference

Europe PubMed Central

2 August 2017

1262-1271

1 reference

Europe PubMed Central

2 August 2017

Endpoints in phase II trials for advanced non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3025267

7 July 2018

Stable disease is a valid end point in clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3025267

7 July 2018

Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3025267

7 July 2018

Cancer statistics, 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3025267

7 July 2018

Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3025267

7 July 2018

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3025267

7 July 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3025267

7 July 2018

End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3025267

7 July 2018

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3025267

7 July 2018

Novel therapies for the treatment of small-cell lung cancer: a time for cautious optimism?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3025267

7 July 2018

Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3025267

7 July 2018

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3025267

7 July 2018

Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive-stage small cell lung carcinoma: a phase II trial of the North Central Cancer Treatment Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3025267

7 July 2018

Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: a phase II study of the North Central Cancer Treatment Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3025267

7 July 2018

Infusion cisplatin chemotherapy and hyperfractionated thoracic radiotherapy for small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3025267

7 July 2018

Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3025267

7 July 2018

Reporting results of cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3025267

7 July 2018

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3025267

7 July 2018

Analysis of survival by tumor response.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3025267

7 July 2018

Regression modelling strategies for improved prognostic prediction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3025267

7 July 2018

Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25526

21 January 2018

The validation of surrogate endpoints in meta-analyses of randomized experiments

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25526

21 January 2018

Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25526

21 January 2018

Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3025267

27 October 2018

Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3025267

27 October 2018

Measurable or assessable disease in lung cancer trials: does it matter?

1 reference

https://pubmed.ncbi.nlm.nih.gov/20960500

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Simulation studies of surrogate endpoint validation using single trial and multitrial statistical approaches

1 reference

https://pubmed.ncbi.nlm.nih.gov/20960500

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improving the efficiency of clinical trials: a medical perspective.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20960500

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Judging New Markers by Their Ability to Improve Predictive Accuracy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20960500

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Criteria of tumor response used in clinical trials of chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20960500

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Response rates, survival, and chemotherapy trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/20960500

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/CNCR.25526

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

2 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34512144&oldid=1645494748"